A study of olezarsen administered subcutaneously in patients with severe hypertriglyceridaemia (sHTG) (NCT05681351)

Please login or create a FREE account to view this content

Educational partners and supporters

Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc. Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals

Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc. Ionis Logo

Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc. Kowa Logo